Kera Capital Partners Inc. Buys Shares of 10,445 Azenta, Inc. $AZTA

Key Points

• Kera Capital Partners Inc. acquired a new stake in Azenta, Inc. by purchasing 10,445 shares valued at approximately $321,000 during the second quarter of the year.
• Azenta's stock recently dropped 5.0% and has a market capitalization of $1.36 billion, with a current stock price of $29.66.
• Analysts have varied opinions on Azenta, with two recommending a Buy rating and three an Equal Weight rating, averaging a price target of $35.75.

Kera Capital Partners Inc. bought a new stake in Azenta, Inc. (NASDAQ:AZTA - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 10,445 shares of the company's stock, valued at approximately $321,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Azenta by 8.9% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,842 shares of the company's stock valued at $168,000 after purchasing an additional 396 shares during the last quarter. Empowered Funds LLC grew its stake in Azenta by 10.5% in the first quarter. Empowered Funds LLC now owns 6,482 shares of the company's stock valued at $225,000 after purchasing an additional 618 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in Azenta by 6.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 12,617 shares of the company's stock worth $437,000 after acquiring an additional 756 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in Azenta by 788.1% in the first quarter. Farther Finance Advisors LLC now owns 968 shares of the company's stock worth $33,000 after acquiring an additional 859 shares in the last quarter. Finally, Quarry LP boosted its holdings in Azenta by 41.5% in the first quarter. Quarry LP now owns 3,120 shares of the company's stock worth $108,000 after acquiring an additional 915 shares in the last quarter. Hedge funds and other institutional investors own 99.08% of the company's stock.

Azenta Stock Down 5.0%

Azenta stock opened at $29.66 on Friday. Azenta, Inc. has a 52 week low of $23.91 and a 52 week high of $55.63. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -12.26 and a beta of 1.65. The stock has a 50-day moving average price of $31.16 and a 200 day moving average price of $30.98.

Azenta (NASDAQ:AZTA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.06. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%.The firm had revenue of $143.94 million during the quarter, compared to the consensus estimate of $149.64 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company's revenue was up .0% compared to the same quarter last year. Research analysts anticipate that Azenta, Inc. will post 0.53 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on AZTA. Raymond James Financial raised Azenta from a "market perform" rating to an "outperform" rating and set a $35.00 price target for the company in a report on Wednesday, August 6th. Stephens began coverage on Azenta in a report on Tuesday, July 22nd. They issued an "equal weight" rating and a $35.00 price target for the company. Finally, Evercore ISI set a $33.00 price target on Azenta and gave the stock an "in-line" rating in a report on Tuesday, August 5th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $35.75.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.